CD276 and head and neck cancer: Nonetheless, this presents a potential opportunity in targeting solid tumors ineligible for PD-1/PD-L1–based therapies, as well as the possibility for dual targeting of B7-H3 and PD-1/PD-L1 which has previously shown antitumor activity in initial studies on head and neck cancers, NSCLC, and prostate cancer (44, 45).